Premium
Interleukin‐10: Is it good or bad for the kidney?
Author(s) -
CHADBAN Steven J,
NIKOLICPATERSON David J
Publication year - 1998
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.1998.tb00368.x
Subject(s) - medicine , immune system , immunology , kidney , macrophage , cytokine , glomerulonephritis , kidney disease , antigen presentation , t cell , biology , in vitro , biochemistry
SUMMARY: Interleukin‐10 (IL‐10) is a cytokine which has been suggested as a possible immunosuppressive treatment for kidney disease. the ability of IL‐10 to suppress antigen presentation to T cells, inhibit the delayed‐type hypersensitivity reaction and to inhibit macrophage production of pro‐inflammatory cytokines provides a logical basis for its use in the treatment of kidney disease. With the exception of Th1‐mediated crescentic glomerulonephritis, however, IL‐10 treatment of experimental kidney disease has produced disappointing results largely due to its stimulatory effects upon the humoral immune response, macrophage Fc‐receptor expression and macrophage proliferation. Paradoxically, there is now evidence to suggest that endogenous production of IL‐10 within the kidney may actually contribute to kidney damage through stimulating mesangial proliferation, immune complex deposition and macrophage infiltration. We await the outcome of studies designed to block IL‐10 function in experimental disease models.